No, lurbinectedin is not approved for breast cancer treatment.
FDA Approval Status
The FDA approved lurbinectedin (brand name Zepzelca) in June 2020 for adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.[1] No approvals exist for breast cancer or other solid tumors outside this indication.
Clinical Trials in Breast Cancer
Ongoing or completed trials have tested lurbinectedin in breast cancer, mainly triple-negative breast cancer (TNBC). Examples include:
- A phase II trial (NCT02454972) evaluating it as monotherapy in advanced breast cancer, showing limited activity with low response rates.[2]
- Combination studies with liposomal doxorubicin (NCT04170989) in metastatic TNBC, which remain investigational and have not led to approval.[3]
No phase III data supports regulatory submission for breast cancer.
Current Use and Off-Label Considerations
Physicians sometimes use lurbinectedin off-label based on trial data, but this lacks FDA endorsement and insurance coverage for breast cancer. Standard breast cancer treatments include chemotherapy (e.g., anthracyclines, taxanes), targeted therapies (e.g., PARP inhibitors for BRCA-mutated cases), and immunotherapy (e.g., pembrolizumab for PD-L1-positive TNBC).
Patents and Market Exclusivity
Lurbinectedin's key U.S. patent (US 7,598,274) covers the compound and expires in 2026, with pediatric exclusivity extending to 2027.[4] No breast cancer-specific patents apply, as approval is SCLC-limited. Check DrugPatentWatch.com for updates on challenges or generics.
[1] FDA.gov - Zepzelca approval announcement (June 15, 2020). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-metastatic-small-cell-lung-cancer
[2] ClinicalTrials.gov - NCT02454972 results summary. https://clinicaltrials.gov/study/NCT02454972
[3] ClinicalTrials.gov - NCT04170989. https://clinicaltrials.gov/study/NCT04170989
[4] DrugPatentWatch.com - Zepzelca patents. https://www.drugpatentwatch.com/p/tradename/ZEPZELCA